Covishield (Covid Vaccine)

Indications

Increases immunity against Corona Virus.

Description

The coronavirus vaccine developed by the University of Oxford is highly effective at stopping people developing Covid-19 symptoms, a large trial shows. Interim data suggests 70% protection, but the researchers say the figure may be as high as 90% by tweaking the dose. The results will be seen as a triumph, but come after Pfizer and Moderna vaccines showed 95% protection. However, the Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two. So the vaccine will play a significant role in tackling the pandemic, if it is approved for use by regulators. The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by [the virus]," said the vaccine's architect, Prof Sarah Gilbert. The UK government has pre-ordered 100 million doses of the Oxford vaccine, and AstraZeneca says it will make three billion doses for the world next year.

Prime Minister Boris Johnson said it was "incredibly exciting news" and that while there were still safety checks to come, "these are fantastic results". Speaking at a Downing Street briefing on Monday evening, Mr Johnson added that the majority of people most in need of a vaccination in the UK might be able to get one by Easter. And Prof Andrew Pollard - director of the Oxford vaccine group- said it had been "a very exciting day" and paid tribute to the 20,000 volunteers in the trials around the world, including more than 10,000 in the UK.

Dosage & Administration

The total number of these vaccine doses, if they are approved to be utilised in the course of time, should be enough to vaccine half of the country's over 1.3 billion population given the fact that most of the vaccine candidates against the coronavirus require two doses.

Therapeutic Class

Vaccines, Anti-sera & Immunoglobulin